Search company, investor...

Hopstem Biotech


Series B | Alive

Total Raised


Last Raised

$40M | 2 yrs ago

About Hopstem Biotech

Hopstem Biotech focuses on human iPSCs/ESCs neural differentiation, cell banking, and cell engineering.

Headquarters Location

3rd Floor, Block 16, Zhongzi Technology Park, No.6 Street No.260 Economic and Technological Development Zone

Hangzhou, Zhejiang , 310018,



Missing: Hopstem Biotech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Hopstem Biotech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Hopstem Biotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Hopstem Biotech is included in 1 Expert Collection, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Latest Hopstem Biotech News

Week in Review: Zai Lab Announces Two In-Licensings with Total Value of $800 Million

Nov 13, 2021

publication date: Nov 13, 2021  |  Deals and Financings Shanghai Zai Lab (NSDQ: ZLAB; HKEX: 9688) announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics (NSDQ: KRTX) (see story ). Zai will have greater  China  rights to two Blueprint next-gen EGFR candidates aimed at non-small cell lung cancer (NSCLC), which Blueprint says have first-in-class potential. Karuna's KarXT is a M1/M4-preferring muscarinic agonist that has shown preliminary benefits for patients with psychosis from schizophrenia and Alzheimer's. KarXT is Zai's first neurologic drug candidate. I-Mab (NSDQ: IMAB) of Shanghai formed a $315 million collaboration with Hubei Jumpcan Pharma (SHA: 600566) to commercialize its human growth hormone in  China (see story ). Jumpcan, which will pay $35 million upfront, specializes in pediatric drugs. Earlier this year, I-Mab started a pivotal China Phase III trial of eftansomatropin alfa as a weekly treatment for pediatric growth hormone deficiency (PGHD). The two companies will split commercialization revenues 50/50, with I-Mab also receiving royalties on sales. Most  China Arbor Biotech, a  China  rights to six of SK's CNS drugs in exchange for $20 million upfront and a $15 million milestone payment. Ignis will also pay royalties on sales. SK plans to acquire 150 million Ignis shares before the end of the year. Hopstem Biotech, a China-US stem-cell therapy company, completed a near $40 million B financing, led by an unnamed VC/PE with participation by Lilly Asia Ventures and YuanBio Venture Capital (see story ). The company's lead product is an off-the-shelf induced pluripotent stem cells (iPSC)-derived human forebrain neural progenitor cell product. Hopstem has built a neural differentiation platform and established a patented method to reprogram iPSC cells. Founded in  2017 by neuroscientists and stem-cell biologists from Johns Hopkins, Hopstem has operations in  Hangzhou Hangzhou 's Ascletis Pharma (HK; 1672) extended its partnership with Suzhou Alphamab to include global rights for its PD-L1 as a viral disease therapy (see story ). Previously, Ascletis held only Greater China rights to the candidate. Ascletis is especially interested in developing the PD-L1 to treat Hepatitis B. Alphamab says ASC22 is a first-in-class subcutaneously injected PD-L1 antibody that it is developing for oncology indications. Ascletis will make upfront and milestone payments to Alphamab, plus royalties of up to 20%, but further specific details were not disclosed. Trials and Approvals  Everest Medicines (HK 1952) reported its novel TROP-2 antibody-drug conjugate met its primary endpoint in a China Phase II trial in metastatic triple-negative breast cancer (TNBC) patients (see story ). In 2019, Everest in-licensed the candidate in an $835 million agreement. Sacituzumab govitecan, which is marketed as Trodelvy® in the  US Gilead (NSDQ: GILD), met its primary endpoint of overall response rate as a third line treatment for TNBC. Earlier this year, Everest began a China Phase III trial of the ADC in patients with metastatic urothelial cancer. Ascletis Pharma (HK: 1672) of  Hangzhou  was approved to start a China Phase II clinical trial of its PD-L1 candidate in HIV-1 patients (see story ). ASC22 will be tested as an immune restoration/functional cure of HIV-1. Earlier this week, Ascletis announced it had added global rights to its agreement with Suzhou Alphamab for the PD-L1 in China viral disease indications. Previously, Ascletis was testing ASC22 (envafolimab) to treat/cure chronic hepatitis B. ASC22 is a single domain PD-L1 antibody with the potential to restore immune responses in patients with chronic viral infections. Gmax Biopharm, a novel Hangzhou antibody company focused on GPCRs, has begun a China Phase I trial of its obesity therapy (see story ). GMA106 is Gmax's second-gen mAb therapy aimed at obesity/T2DM/NASH. It combines Gmax's GPCR mAb with its M-Body technology, which aims at two different targets for better efficacy. In this case the M-Body pairs an anti-GIPR antibody fused with a GLP-1 peptide. Patients in the Phase I trial will be given a single dose of GMA106. The trial will be structured as a placebo controlled, double blind, randomized, dose escalating study. Nanjing IASO Bio dosed the first patient in a China Phase I/II trial of its fully human CD19/CD22 CAR-T cell therapy (see story ). The trial will enroll patients with CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma. IASO said the candidate is the first fully human dual-targeted CAR-T cell therapy approved to start clinical trials. IASO plans to start a second trial of the CD19/CD22 CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Disclosure: none.

Hopstem Biotech Frequently Asked Questions (FAQ)

  • Where is Hopstem Biotech's headquarters?

    Hopstem Biotech's headquarters is located at 3rd Floor, Block 16, Zhongzi Technology Park, No.6 Street No.260, Hangzhou.

  • What is Hopstem Biotech's latest funding round?

    Hopstem Biotech's latest funding round is Series B.

  • How much did Hopstem Biotech raise?

    Hopstem Biotech raised a total of $57.4M.

  • Who are the investors of Hopstem Biotech?

    Investors of Hopstem Biotech include bioVENTURE, Hillhouse Capital Management, Lilly Asia Ventures, YuanBio Venture Capital, Huacheng Venture Capital Partnership and 7 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.